Vytorin and Inflammatory carcinoma of the breast - a phase IV clinical study of FDA data

Summary:

Inflammatory carcinoma of the breast is reported only by a few people who take Vytorin.

The phase IV clinical study analyzes which people take Vytorin and have Inflammatory carcinoma of the breast. It is created by eHealthMe based on reports of 19,114 people who have side effects while taking Vytorin from the FDA, and is updated regularly.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Aug, 08, 2022

19,114 people reported to have side effects when taking Vytorin.
Among them, 4 people (0.02%) have Inflammatory carcinoma of the breast.


What is Vytorin?

Vytorin has active ingredients of ezetimibe; simvastatin. It is often used in high blood cholesterol. eHealthMe is studying from 19,592 Vytorin users for its effectiveness, alternative drugs and more.

What is Inflammatory carcinoma of the breast?

Inflammatory carcinoma of the breast is found to be associated with 147 drugs and 80 conditions by eHealthMe.

Number of Vytorin and Inflammatory carcinoma of the breast reports submitted per year:

Could Vytorin cause Inflammatory carcinoma of the breast?

Time on Vytorin when people have Inflammatory carcinoma of the breast *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 100 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Age of people who have Inflammatory carcinoma of the breast when taking Vytorin *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 100 %
  • 60+: 0.0 %

Common drugs people take besides Vytorin *:

  1. Metoprolol Tartrate: 2 people, 50.00%
  2. Enalapril Maleate: 2 people, 50.00%
  3. Aspirin: 1 person, 25.00%

Common side effects people have besides Inflammatory carcinoma of the breast *:

  1. Metastases To Spine (cancer spreads to spine): 4 people, 100.00%
  2. Metastases To Lung (cancer spreads to lung): 4 people, 100.00%
  3. Metastases To Liver (cancer spreads to liver): 4 people, 100.00%
  4. Hair Loss: 3 people, 75.00%
  5. Cellulitis (infection under the skin): 3 people, 75.00%
  6. Breast Cancer Metastatic: 3 people, 75.00%
  7. Metastases To Central Nervous System (cancer spreads to central nervous system): 2 people, 50.00%
  8. Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 2 people, 50.00%
  9. Cerebellar Tumor: 2 people, 50.00%
  10. Neck Pain: 1 person, 25.00%

Common conditions people have *:

  1. Acute Coronary Syndrome (acute chest pain and other symptoms that happen because the heart does not get blood): 4 people, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Vytorin and have Inflammatory carcinoma of the breast?

Check whether Inflammatory carcinoma of the breast is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of Vytorin:

Inflammatory carcinoma of the breast treatments and more:

COVID vaccines that are related to Inflammatory carcinoma of the breast:

How severe was Inflammatory carcinoma of the breast and when was it recovered:

Expand to all the drugs that have ingredients of ezetimibe; simvastatin:

All the drugs that are associated with Inflammatory carcinoma of the breast:

All the conditions that are associated with Inflammatory carcinoma of the breast:

How the study uses the data?

The study uses data from the FDA. It is based on ezetimibe; simvastatin (the active ingredients of Vytorin) and Vytorin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: